Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phosphocreatine myocardial protection in high-risk valvular surgery
ChiCTR1800016141Phase 4Not yet recruiting
- Sponsor
- Fuwai Hospital
- Start
- Jun 2017
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in Cardiac valve disease (VHD) comparing Phosphocreatine group with Placebo group (2 arms). Primary endpoints: Troponin I, NT-proBNP and 1 more. Planned start Jun 2017; status: not yet recruiting.
02
Drugs
phosphocreatine
03
Conditions
Cardiac valve disease (VHD)
Beyond the preview
Go deeper on ChiCTR1800016141.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800016141.